

# SEE WHAT LIES BENEATH BREAST CANCER

Breast cancers are commonly categorized into **3 subtypes**<sup>1</sup>:



- (1)** HR+/HER2- (hormonal receptor-positive/ human epidermal growth factor receptor 2-negative);
- (2)** HER2+; and
- (3)** triple negative.



Recently, scientists discovered that genetic mutations, such as those in the **PIK3CA gene**, are important in HR+/HER2- advanced breast cancer. Patients should know what really lies beneath their breast cancer so that they can receive personalized treatment.

## PIK3CA mutation is common in breast cancer

The *PIK3CA* gene is important for many cell activities, including cell growth and cell death.<sup>2</sup>




Therefore, close to **1 in 4** breast cancer patients has this mutation, making it one of the most common genetic abnormalities in breast cancer.<sup>5</sup>

## PIK3CA mutation is associated with poor treatment response and survival outcomes


Compared with those without the mutation, patients with HR+ /HER2- advanced or metastatic breast cancer carrying the PIK3CA mutation:



Respond worse to chemotherapy and may develop resistance to hormone therapy<sup>6,7</sup>



Have a higher risk of their cancer spreading to the brain (brain metastasis)<sup>8</sup>



Have poorer survival<sup>9</sup>

## TAKE ACTION TEST FOR PIK3CA MUTATIONS TODAY

Knowing what lies beneath your breast cancer helps your physician to personalize treatment to your needs.



Testing for PIK3CA mutations in HR+/HER2- advanced breast cancer patients is supported by **major international treatment guidelines**.<sup>10,11</sup>



### References

1. Sims AH, et al. *Nat Clin Pract Oncol* 2007;4:516-525.
2. Samuels Y, Waldman T. *Curr Top Microbiol Immunol* 2010;347:21-41.
3. The Hong Kong Breast Cancer Foundation. Hong Kong Breast Cancer Registry Report No. 11 (Issue 2019). Available at: [https://www.hkbcf.org/en/our\\_research/main/468/upload/category/468/self/5d939ba37488f.pdf](https://www.hkbcf.org/en/our_research/main/468/upload/category/468/self/5d939ba37488f.pdf) (Accessed November 2020).
4. The Cancer Genome Atlas Network. *Nature* 2012;490:61-70.
5. Loi S, et al. *Proc Natl Acad Sci U S A* 2010;107:10208-10213.
6. Brown KK and Toker A. *F1000Prime Rep* 2015;7:13.
7. Miller TW, et al. *J Clin Invest* 2010;120:2406-2413.
8. Fitzgerald DM, et al. *Ann Oncol* 2019;30:v110 (suppl 5).
9. Mosele F, et al. *Ann Oncol* 2020;31:377-386.
10. National Comprehensive Cancer Network. NCCN Guidelines. Available at: [https://www.nccn.org/professionals/physician\\_gls/default.aspx](https://www.nccn.org/professionals/physician_gls/default.aspx) (Accessed November 2020).
11. Thomssen C, et al. *Breast Care* 2020;15:82-95.